News

A study reveals the intricate decision-making process caregivers face when considering gene therapy for Duchenne muscular dystrophy, emphasizing shared input and personal experiences.

Catch up on any of the neurology news headlines you may have missed in October 2025, compiled into 1 place by the NeurologyLive® team.

Although their knowledge, experience, and access to genetic counselors varied, most licensed OB/GYNs across Ohio reported routinely offering carrier screening for spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Experts discussed the benefits and challenges of once-nightly versus twice-nightly oxybate regimens for narcolepsy, emphasizing adherence, patient lifestyle, and comorbidity considerations. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

A study reveals that genetic counseling significantly empowers individuals at risk for frontotemporal dementia, highlighting the need for best practice guidelines.

Experts discussed REFRESH study data highlighting oxybates’ tolerability, effectiveness, and potential to reduce stimulant burden in patients with narcolepsy. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending November 8, 2025. [WATCH TIME: 4 minutes]

A new study presented at the National Society of Genetic Counselors Annual Conference highlights strong interest among individuals at risk for Huntington disease in undergoing modifier gene testing, underscoring the growing role of genetic insights in personal and clinical decision-making.

Axsome Therapeutics advances AXS-05 for Alzheimer agitation, showcasing promising trial results and potential for treating major depressive disorder.

A new study presented at NSGC 2025 showed that patients living with amyotrophic lateral sclerosis considering medical aid in dying often experienced emotional and logistical challenges with the process.

Experts discussed the prevalence of comorbidities in narcolepsy and how targeted therapies, particularly oxybate, can improve both sleep quality and associated psychiatric symptoms. [WATCH TIME: 9 minutes]

A recent study highlights the link between genetic neurodevelopmental disorders and increased gastrointestinal issues in pediatric patients, emphasizing the need for targeted care.

A new study reveals that early treatment with the Nerivio wearable significantly enhances migraine relief, doubling efficacy outcomes for patients.

Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the global implications of environmental exposure.

Experts discussed findings, presented at the 2025 World Sleep Congress, showing how once-nightly oxybate improved adherence, quality of life, and partner burden in patients with narcolepsy. [WATCH TIME: 9 minutes]

Spingogenix presents promising data on SPG302, a daily tablet showing cognitive improvements in ALS patients with excellent safety profiles.

The chief medical officer at Dyne Therapeutics discussed the scientific rationale and clinical progress of z-basivarsen an antisense oligonucleotide therapy designed to correct mis-splicing in myotonic dystrophy type 1. [WATCH TIME: 5 minutes]

A 2025 study published in Neurology® found that people with both gum disease and dental cavities face significantly higher long-term risks of stroke and major cardiovascular events compared with those with good oral health.

An investigator at Kuakini Health Systems spoke about the global importance of the Honolulu-Asia Aging Study, highlighting its history and findings, including data surrounding the diagnosis of neurodegenerative diseases. [WATCH TIME: 11 minutes]

Feedback from the FDA allows CervoMed to move forward with the proposed primary and secondary end point of the phase 3 trial assessing neflamapimod in dementia with Lewy bodies.

FDA issues a complete response letter for Biohaven's troriluzole, a potential treatment for spinocerebellar ataxia, citing data concerns.

New clinical trial results show LT3001's promise in treating acute ischemic stroke, demonstrating safety and improved patient outcomes without complications.

The associate professor of physical medicine and rehabilitation at Virginia Commonwealth University discussed his passion for educating others about electrodiagnosis and ultrasound in neuromuscular disorders.

A physician assistant who specializes in neurology previewed her upcoming presentation on evaluating patients with headache at the 2025 Baptist Miami Neuroscience Symposium.

The neuroscience program coordinator at Loyola University Medical Center talked about a recent global nurse survey for those caring for patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]

A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.